Patients with multiple system atrophy
Conditions
Interventions
Patients with administration of ubiquinol
Sponsors
Department of Neurology, the University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects diagnosed as probable or possible multiple system atrophy on the basis of the Gilman criteria 2. Subjects in a genetic test with homozygous or compound heterozygous mutations in the COQ2 gene 3. Male or female subjects between the ages of 30 and 80 at time of informed consent 4. Subjects who can get an informed consent from themselves 5. Subjects who can be admitted to the university of Tokyo hospital
Exclusion criteria
Exclusion criteria: 1. Subjects having received ubiquinone, ubiquinol, or idebenone 2. Subjects with severe liver dysfunction (Child-Pugh class A-C) 3. Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period 4. Subjects who have received any investigational drug within 12 weeks prior to informed consent 5. Subjects who are determined as unfit for the study by attending physicians for reasons other than those stated above
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2. Coenzyme q10 levels in plasma, blood mononuclear cells, and cerebrospinal fluid 1. Adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. UMSARS Part II 2. Urinary 8-OHdG 3. Glucose metabolism of the cerebellum on FEG-PET 4. Oxygen metabolism of the cerebellum on 15O-PET | — |
Countries
Japan
Contacts
Public ContactJun Mitsui
The University of Tokyo Hospital Department of Neurology
Outcome results
None listed